This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.
Study Type
OBSERVATIONAL
Enrollment
423
Progression-free survival
Time frame: 18 months
Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment
Time frame: 18 months
Modality of treatment with Avastin (dose, duration, associated chemotherapy)
Time frame: 18 months
Overall survival
Time frame: 18 months
Safety: Incidence of adverse events
Time frame: 18 months
Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire
Time frame: 18 months
Treatment of non-squamous NSCLC in clinical practice
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Abbeville, France
Unnamed facility
Agen, France
Unnamed facility
Aix-en-Provence, France
Unnamed facility
Aix-en-Provence, France
Unnamed facility
Alès, France
Unnamed facility
Ambilly, France
Unnamed facility
Amiens, France
Unnamed facility
Amilly, France
Unnamed facility
Angers, France
Unnamed facility
Annecy, France
...and 142 more locations